New York State Common Retirement Fund Sells 90,585 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS)

New York State Common Retirement Fund decreased its position in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) by 81.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,593 shares of the biotechnology company’s stock after selling 90,585 shares during the period. New York State Common Retirement Fund’s holdings in Coherus BioSciences were worth $28,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of CHRS. Geode Capital Management LLC grew its holdings in shares of Coherus BioSciences by 7.7% in the third quarter. Geode Capital Management LLC now owns 2,565,145 shares of the biotechnology company’s stock valued at $2,668,000 after purchasing an additional 182,914 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Coherus BioSciences by 13.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 964,327 shares of the biotechnology company’s stock worth $1,003,000 after purchasing an additional 116,217 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in shares of Coherus BioSciences by 344.1% during the third quarter. Los Angeles Capital Management LLC now owns 930,132 shares of the biotechnology company’s stock worth $967,000 after acquiring an additional 720,672 shares during the last quarter. XTX Topco Ltd grew its stake in shares of Coherus BioSciences by 74.5% during the third quarter. XTX Topco Ltd now owns 473,517 shares of the biotechnology company’s stock worth $492,000 after acquiring an additional 202,084 shares during the last quarter. Finally, Tyche Wealth Partners LLC grew its stake in shares of Coherus BioSciences by 23.6% during the fourth quarter. Tyche Wealth Partners LLC now owns 266,766 shares of the biotechnology company’s stock worth $368,000 after acquiring an additional 50,864 shares during the last quarter. Institutional investors own 72.82% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Coherus BioSciences in a research report on Thursday, January 23rd. Robert W. Baird increased their price objective on Coherus BioSciences from $4.00 to $6.00 and gave the company an “outperform” rating in a research note on Thursday, December 5th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $5.38.

Coherus BioSciences Trading Down 3.4 %

NASDAQ CHRS opened at $1.00 on Friday. The stock has a fifty day simple moving average of $1.27 and a 200-day simple moving average of $1.19. Coherus BioSciences, Inc. has a twelve month low of $0.66 and a twelve month high of $2.64. The stock has a market cap of $115.31 million, a PE ratio of -12.44 and a beta of 0.81.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.